ReviewNature chemical biology2026
Adaptive mechanisms and emerging cancer therapeutics for CDK2 inhibitors.
Review in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approvals of four CDK4/6 (cyclin-dependent kinases 4 and 6) inhibitors by the US Food and Drug Administration-palbociclib, abemaciclib, ribociclib and trilaciclib-as anticancer or supportive therapies establish the critical role of CDKs in regulating the cell cycle and cancer progression. However, the emergence of drug-resistant cancers underscores the adaptability and plasticity of this cellular pathway, highlighting the need for additional therapeutic strategies. CDK2, the key kinase activated downstream of CDK4/6, has emerged as a prominent pharmaceutical target, with numerous selective inhibitors reported in recent years. This Perspective discusses the adaptive plasticity of cell-cycle control in cancer cells and then highlights current strategies to target newly emerging CDK2 druggable pockets-including orthosteric, substrate-binding and allosteric sites-with an emphasis on chemical biology approaches, aiming to inspire the next generation of CDK2 inhibitors and kinase-targeted therapies more broadly.
Identifiers
42675128What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.